Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Sesen Bio, Inc. (SESN)

Sesen Bio is a late-stage clinical company that purports to advance targeted fusion protein (TFP) therapeutics for cancer treatments.